Business Context and Reporting Period
This Form 8-K was filed by Lion Biotechnologies, Inc. (not IOVANCE BIOTHERAPEUTICS, INC.) on December 28, 2015. The report details a corporate action regarding the annual year-end employee option grant program.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to equity compensation:
- Option Exercise Price: $7.58 per share (closing trading price on December 28, 2015).
- Total Options Granted to Named Executive Officers: 107,677 shares.
Material Changes and Executive Compensation
As part of the annual grant program, options were issued to three named executive officers with the following allocation:
- Elma Hawkins, Ph.D. (CEO): 58,939 shares.
- Molly Henderson (CFO): 21,116 shares.
- James Bender, Ph.D. (VP-Manufacturing): 27,622 shares.
Vesting Schedule:
- One-third of the options vest on December 28, 2016.
- The remaining two-thirds vest in eight equal quarterly installments over the subsequent two years.
- Vesting is contingent upon continued employment.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on future performance, or specific risk factors beyond the standard employment contingency for option vesting.
Investor Verification Checklist
- Verify the correct registrant name is Lion Biotechnologies, Inc., as the input metadata referenced IOVANCE BIOTHERAPEUTICS, INC.
- Confirm the total number of options outstanding post-grant in subsequent filings.
- Monitor the vesting schedule to track future dilution impacts.
- Review the stock price performance relative to the $7.58 exercise price to assess option value.